VON WILLEBRAND DISEASE, TYPE 3
Clinical trials for VON WILLEBRAND DISEASE, TYPE 3 explained in plain language.
Never miss a new study
Get alerted when new VON WILLEBRAND DISEASE, TYPE 3 trials appear
Sign up with your email to follow new studies for VON WILLEBRAND DISEASE, TYPE 3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a simple shot replace IV treatments for severe bleeding disorder?
Disease control Recruiting nowThis study tests if Emicizumab (Hemlibra), a medicine given as a shot under the skin, can safely prevent bleeding in people with severe von Willebrand disease (VWD) or VWD with hemophilia A. Current treatments require IV infusions, which are harder to use. The trial will check ho…
Matched conditions: VON WILLEBRAND DISEASE, TYPE 3
Phase: PHASE1 • Sponsor: Bleeding and Clotting Disorders Institute Peoria, Illinois • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
New shot may cut bleeds in rare blood disorder
Disease control Recruiting nowThis study tests a medicine called emicizumab, given as a shot, to prevent bleeding in people with Type 3 von Willebrand disease, a severe blood clotting disorder. About 75 people aged 1 month and older will take part. Some will get emicizumab, while others continue their usual c…
Matched conditions: VON WILLEBRAND DISEASE, TYPE 3
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
New study tracks bleeding episodes and daily life impact in rare bleeding disorder
Knowledge-focused Recruiting nowThis study is for people with Type 3 von Willebrand disease, a rare bleeding disorder. Researchers want to see how often bleeding happens and how it affects quality of life while participants receive their usual preventive treatment. About 40 people will be observed for at least …
Matched conditions: VON WILLEBRAND DISEASE, TYPE 3
Sponsor: Hoffmann-La Roche • Aim: Knowledge-focused
Last updated May 13, 2026 16:01 UTC